A Phase 3 interventional study of Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU) and Platinum (Cisplatin or Carboplatin) + 5-FU in Head and Neck Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 70 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-23.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing fluorouracil in Head and Neck Neoplasms — 4 open to participants now, 5 under way, none of them phase 3. Fluorouracil · Head and Neck Neoplasms.
Among the 44 studies testing fluorouracil in Head and Neck Neoplasms, this one is the 2nd largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2004, is one of 8 in phase 3, and was the 15th registered.
2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.
Browse Head and Neck Neoplasms studies →4 of the 44 studies testing fluorouracil in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18–75
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–75
By country, each count listing its studies:
Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →
Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 28 · Phase 3 10 · Phase 4 3
First in 1988; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 442 is above the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 40 across the 42 interventional studies. Of the 36 that completed or were terminated, 15 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 44 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 6 studies filed under Head and Neck Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing fluorouracil in Head and Neck Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05358548Rutgers, The State University of New JerseyATATcH Alternating Treatment Plans for Advanced Cancer | 2027-05-01 |
| NCT07158164Rutgers, The State University of New JerseyDPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment | 2027-07-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies testing fluorouracil in Head and Neck Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with recurrent or metastatic head and neck cancer. Overall survival will be taken as the primary measure of efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)
Drug: Platinum (Cisplatin or Carboplatin) + 5-FU
Drug page: Fluorouracil
Subjects in will receive initial dose of 400 mg/m\^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m\^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
Drug pages: Platinum Compounds · Fluorouracil
All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
Overall Survival Time (OS)
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
Time frame: time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
Progression-free Survival Time (PFS)
Duration from randomization until radiological progression according to investigator (based on modified World Health Organisation (WHO) criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
Time frame: time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
Best Overall Response
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments according to investigator (based on modified WHO criteria).
Time frame: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
Disease Control
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments according to investigator (based on modified WHO criteria).
Time frame: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
Time to Treatment Failure
Time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment.
Time frame: Time from randomization to treatment failure or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
Duration of Response
Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.
Time frame: time from first assessment of Complete Response or Partial Response to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.
Time frame: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
Quality of Life Assessment (EORTC QLQ-C30) Social Functioning
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of social functioning.
Time frame: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
Safety - Number of Patients Experiencing Any Adverse Event
Please refer to Adverse Events section for further details
Time frame: time from first dose up to 30 after last dose of study treatment, reported between day of first dose of study treatment, 22 Dec 2004, until cut-off date 12 Mar 2007
First/last subject(informed consent): 14Dec 2004/28 Dec2005. Clinical cut-off: 12 Mar 2007. 80 centers in Europe: Austria (3), Belgium (5), Czech Republic (2), France (12),Germany (8), Hungary (4), Italy (5), Netherlands (4), Poland (5), Portugal (3), Russia (4), Slovakia (2), Spain (9), Sweden (3), Switzerland (3), UK (4), and Ukraine (4).
| Milestone | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Started | 222 | 220 |
| Completed | 215 | 219 |
| Not completed | 7 | 1 |
| Withdrew: Investigational study phase ongoing | 7 | 1 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
| months | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Overall Survival Time (OS) | 10.1 (8.6 to 11.2) | 7.4 (6.4 to 8.3) |
Duration from randomization until radiological progression according to investigator (based on modified World Health Organisation (WHO) criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
| months | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Progression-free Survival Time (PFS) | 5.6 (5.0 to 6.0) | 3.3 (2.9 to 4.3) |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments according to investigator (based on modified WHO criteria).
| percentage of participants | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Best Overall Response | 35.6 (29.3 to 42.3) | 19.5 (14.5 to 25.4) |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments according to investigator (based on modified WHO criteria).
| percentage of participants | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Disease Control | 81.1 (75.3 to 86.0) | 60.0 (53.2 to 66.5) |
Time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment.
| months | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Time to Treatment Failure | 4.8 (4.0 to 5.6) | 3.0 (2.8 to 3.4) |
Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.
| months | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Duration of Response | 5.6 (4.7 to 6.0) | 4.7 (3.5 to 5.9) |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.
| scores on a scale | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| At baseline | 50.74 ± 3.519 | 45.15 ± 3.745 |
| At cycle 3 | 52.68 ± 3.724 | 45.48 ± 4.153 |
| Month 6 | 55.30 ± 4.282 | 42.49 ± 5.959 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of social functioning.
| scores on a scale | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| At baseline | 62.14 ± 4.459 | 62.05 ± 4.730 |
| At cycle 3 | 64.64 ± 4.663 | 60.67 ± 5.176 |
| Month 6 | 61.27 ± 5.347 | 65.72 ± 7.122 |
Please refer to Adverse Events section for further details
| participants | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Safety - Number of Patients Experiencing Any Adverse Event | 218 | 208 |
Collected over Time from first dose up to 30 days after the last dose of study treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab Plus Chemotherapy | — | 110/219 (50.2%) | 214/219 (97.7%) |
| Chemotherapy Alone | — | 102/215 (47.4%) | 198/215 (92.1%) |
| Event | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/219 | 11/215 |
| AnaemiaBlood and lymphatic system disorders | 5/219 | 10/215 |
| NeutropeniaBlood and lymphatic system disorders | 3/219 | 10/215 |
| PneumoniaInfections and infestations | 10/219 | 4/215 |
| Febrile neutropeniaBlood and lymphatic system disorders | 8/219 | 9/215 |
| DehydrationMetabolism and nutrition disorders | 9/219 | 3/215 |
| PyrexiaGeneral disorders | 2/219 | 7/215 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/219 | 7/215 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/219 | 6/215 |
| Mucosal inflammationGeneral disorders | 5/219 | 6/215 |
| Event | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| NauseaGastrointestinal disorders | 119/219 | 100/215 |
| AnaemiaBlood and lymphatic system disorders | 92/219 | 111/215 |
| VomitingGastrointestinal disorders | 84/219 | 79/215 |
| NeutropeniaBlood and lymphatic system disorders | 83/219 | 77/215 |
| RashSkin and subcutaneous tissue disorders | 61/219 | 4/215 |
| DiarrhoeaGastrointestinal disorders | 56/219 | 33/215 |
| AstheniaGeneral disorders | 56/219 | 47/215 |
| AnorexiaMetabolism and nutrition disorders | 54/219 | 31/215 |
| Mucosal inflammationGeneral disorders | 50/219 | 38/215 |
| FatigueGeneral disorders | 49/219 | 44/215 |
| Age, Categorical(Participants) | Cetuximab Plus Chemotherapy | Chemotherapy Alone | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 183 | 182 | 365 |
| >=65 years | 39 | 38 | 77 |
| Age, Continuous(years) | Cetuximab Plus Chemotherapy | Chemotherapy Alone | Total |
|---|---|---|---|
| Mean | 57.1 ± 8.0 | 56.7 ± 8.7 | 56.9 ± 8.3 |
| Sex: Female, Male(Participants) | Cetuximab Plus Chemotherapy | Chemotherapy Alone | Total |
|---|---|---|---|
| Female | 25 | 18 | 43 |
| Male | 197 | 202 | 399 |
| Region of Enrollment(participants) | Cetuximab Plus Chemotherapy | Chemotherapy Alone | Total |
|---|---|---|---|
| Portugal | 3 | 6 | 9 |
| Slovakia | 3 | 1 | 4 |
| Spain | 38 | 41 | 79 |
| Ukraine | 18 | 16 | 34 |
| Austria | 4 | 10 | 14 |
| Russian Federation | 9 | 7 | 16 |
| United Kingdom | 4 | 5 | 9 |
| Switzerland | 4 | 4 | 8 |
| Italy | 14 | 12 | 26 |
| France | 45 | 31 | 76 |
| Czech Republic | 4 | 5 | 9 |
| Hungary | 19 | 24 | 43 |
| Belgium | 14 | 16 | 30 |
| Poland | 18 | 18 | 36 |
| Germany | 18 | 14 | 32 |
| Netherlands | 4 | 6 | 10 |
| Sweden | 3 | 4 | 7 |
The record gives a start of Dec 2004, a primary completion of Mar 2007 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 4 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluorouracil · Platinum Compounds
Merck KGaA, Darmstadt, Germany →